READ: Featured Drug Insights: November 2025
Your source for all Prime Therapeutics' November 2025 Drug Insights publications.
Prime Therapeutics (Prime) provides you with regular updates on the drug pipeline as well as next-generation clinical information and hot topics. The following Drug Insights publications for November 2025 will keep you informed on what’s trending now and trending clinical topics.
Released Nov. 10, 2025
A monthly report of the most notable drugs that may significantly affect the populations we serve. Drug highlights this month are marnetegragene autotemcel, onasemnogene abeparvovec and more.
Released Nov. 12, 2025
Cell & Gene Pipeline Outlook: November 2025
Our newest publication tracks what is ahead in the cell and gene therapy (CGT) pipeline over the next few years. Check out our inaugural edition for insights on cell therapies — including CAR-T — and gene therpies poised for growth.
more.
Released Nov. 14, 2025
Providing a clinical deep dive into a select high-cost drug in the pipeline, this month's profile features Tividenofusp alfa (DNL31), an enzyme replacement therapy (ERT) to treat Hunter Syndrome.
Released Nov. 14, 2025
Featuring commentary by Simone Ndujiuba, PharmD, BCOP, on developments in the oncology space, this installment explores the 21st Century Cures Act (Cures Act) and how it has accelerated medical innovation through updated regulatory frameworks and enhanced data sharing.
Released Nov. 19, 2025
FDA Decisions Expected: December 2025
A breakdown of FDA decisions expected of new drugs anticipated to hit the market, this edition covers lisocabtagene maraleucel, lerodalcibep and more.
Released Nov. 20, 2025
A quartely view of the GLP-1 pipeline and anticipated indications, offering a credible clinical snapshot of what's ahead. See what's coming in the emerging GLP-1 landscape.
Looking for previous 2025 drug insights publications?
Simply click on the month to access past editions of our drug insights.
Login Portals
Compliance / Legal
Company
